1. World Stroke Organization: Global Stroke Fact Sheet 2025.
- Author
-
Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, F Grupper M, and Rautalin I
- Abstract
Background: Among non-communicable disorders (NCDs), stroke remains the second leading cause of death and the third leading cause of death and disability combined (as expressed by disability-adjusted life-years lost-DALYs) in the world., Aims: The study was aimed to estimate global, regional and nationa burden of stroke and its risk factors from 1990 to 2021., Methods: Finding presented in this paper were derived mainly from the Global Burden of Disease 2021 Study on stroke burden published in The Lancet Neurology 2024:23:973-1003., Results: The estimated global cost of stroke is over US$890 billion (0.66% of the global GDP). From 1990 to 2021, the burden (in terms of the absolute number of cases) increased substantially (70.0% increase in incident strokes, 44.0% deaths from stroke, 86.0% prevalent strokes, and 32% DALYs), with the bulk of the global stroke burden (87.0% of deaths and 89.0% of DALYs) residing in lower-income and lower-middle-income countries (LMICs). Stroke attributable to metabolic risks constituted 69.0% of all strokes, environmental risks constituted 37.0%, and behavioral risks constituted 35.0%., Conclusion: This World Stroke Organization (WSO) Global Stroke Fact Sheet 2025 provides the most updated information that can be used to inform communication with all internal and external stakeholders; all statistics have been reviewed and approved for use by the WSO Executive Committee and leaders from the Global Burden of Disease research group., Competing Interests: Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: V.L.F. declares that free Stroke Riskometer app and PreventS-MD are owned and copyrighted by PreventS-MD Ltd (a spin-off of the Auckland University of Technology Ventures Ltd), he is a Chief Scientific Adviser and shareholder of. B.N. has received honoraria for Data Safaty and Monitoring Board work for the HOVID trial (Simbec-Orion). None of the other authors declared any conflict of interest.
- Published
- 2025
- Full Text
- View/download PDF